The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer
Our study illustrated the characterization of APOBEC mutagenesis in multiple cancer types and highlighted its potential value as a prognostic and immunotherapeutic biomarker for PAAD, and finally demonstrated the effectiveness of irinotecan, an inhibitor of APMs, in vivo and in vitro experiments.
Authors
- Yongjie Xie (ORCID: https://orcid.org/0009-0003-3595-0866)
- Weishuai Liu (ORCID: https://orcid.org/0000-0002-9549-5020)
- Parhat Kaysar
- Bo Ni (ORCID: https://orcid.org/0000-0001-8976-2551)
- Weihao Zhang (ORCID: https://orcid.org/0000-0002-9301-8538)
- Gang Shen (ORCID: https://orcid.org/0000-0001-6845-2191)
- Ziyun Liu (ORCID: https://orcid.org/0000-0003-2992-7590)
- Xiaobin Shang (ORCID: https://orcid.org/0000-0002-7155-9499)
- Yaoyao Zhou (ORCID: https://orcid.org/0000-0001-5104-0457)
- Xiaozhou Yu (ORCID: https://orcid.org/0000-0002-9187-2896)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Genomics
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1016/j.ygeno.2025.111098
- Primary Topic
- Single-cell and spatial transcriptomics
- Type
- article
- Field-Weighted Citation Impact
- 0.00